Guggenheim Ascending?
After finishing the year advising on the Disney acquisition of Fox (66B) Guggenheim has pulled off 2 more multi-billion dollar deals with the latest being Sanofi's acquisition of Bioverativ (11B). Many on this forum have said that Guggenheim is not an EB, is this changing and are exit opps improving as time goes on?
Maybe its the Milken effect.
Guggenheim has had a lot of recent success in pharma in particular (i.e. Pfizer, Sanofi like you mentioned) thanks to Alan Schwartz. TMT is strong as well; would be interested to hear how their other groups stack up from anyone working there
I'd say its clear that their HC and TMT groups are their best
Consumer Retail and Power & Energy seem to be solid as well.
In addition to this, they were the sole advisor on St. Jude Medical's sale to Abbot (30B) which closed a year ago. A boutique landing a sole advisor role on a public company sale is very, very impressive in my mind. Schwartz is absolutely killing it...
Any idea how the HC/TMT groups exit? Are the opps becoming stronger as the firm gets more established?
I would be interested in this as well. There is a lot of conflicting info about their placement. Seems like they would place well given their recent success.
Over last few years they hired several senior guys across pharma, medical devices and services from BBs. That's showing in lot of the deals they are doing across the healthcare space
Delete
Quia ab eius voluptas accusantium tenetur voluptas nihil. Dolores sit et quos neque. Nemo ut eos est. Dignissimos soluta vel beatae fugiat ipsam ab officia magni. Est qui rerum doloribus ab nesciunt.
Et et corporis vel quia. Qui expedita dolor non quia quis consequatur libero quae.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...